1. Home
  2. PRLD vs HFBL Comparison

PRLD vs HFBL Comparison

Compare PRLD & HFBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • HFBL
  • Stock Information
  • Founded
  • PRLD 2016
  • HFBL 1924
  • Country
  • PRLD United States
  • HFBL United States
  • Employees
  • PRLD N/A
  • HFBL N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • HFBL Savings Institutions
  • Sector
  • PRLD Health Care
  • HFBL Finance
  • Exchange
  • PRLD Nasdaq
  • HFBL Nasdaq
  • Market Cap
  • PRLD 48.6M
  • HFBL 41.3M
  • IPO Year
  • PRLD 2020
  • HFBL N/A
  • Fundamental
  • Price
  • PRLD $0.82
  • HFBL $13.15
  • Analyst Decision
  • PRLD Strong Buy
  • HFBL
  • Analyst Count
  • PRLD 2
  • HFBL 0
  • Target Price
  • PRLD $4.50
  • HFBL N/A
  • AVG Volume (30 Days)
  • PRLD 121.2K
  • HFBL 1.7K
  • Earning Date
  • PRLD 08-11-2025
  • HFBL 07-29-2025
  • Dividend Yield
  • PRLD N/A
  • HFBL 3.97%
  • EPS Growth
  • PRLD N/A
  • HFBL 6.78
  • EPS
  • PRLD N/A
  • HFBL 1.26
  • Revenue
  • PRLD $7,000,000.00
  • HFBL $20,802,000.00
  • Revenue This Year
  • PRLD N/A
  • HFBL N/A
  • Revenue Next Year
  • PRLD N/A
  • HFBL N/A
  • P/E Ratio
  • PRLD N/A
  • HFBL $10.91
  • Revenue Growth
  • PRLD N/A
  • HFBL 1.50
  • 52 Week Low
  • PRLD $0.61
  • HFBL $11.75
  • 52 Week High
  • PRLD $6.80
  • HFBL $14.25
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 44.66
  • HFBL 43.70
  • Support Level
  • PRLD $0.81
  • HFBL $13.52
  • Resistance Level
  • PRLD $1.00
  • HFBL $13.69
  • Average True Range (ATR)
  • PRLD 0.08
  • HFBL 0.07
  • MACD
  • PRLD 0.00
  • HFBL -0.04
  • Stochastic Oscillator
  • PRLD 20.48
  • HFBL 0.00

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About HFBL Home Federal Bancorp Inc. of Louisiana

Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.

Share on Social Networks: